Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | PRNP | P04156 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316163 | 0.83 | GAA (0.72) | ALDH1A1 | |
| SCHEMBL22345507 | 0.77 | RXFP1 (0.55) | ALDH1A1HPGDHSD17B10RXFP1ALOX15 | |
| SCHEMBL7996729 | 0.74 | ALDH1A1 (0.76) | ALDH1A1 | |
| SCHEMBL2977982 | 0.74 | ALDH1A1 (0.76) | ALDH1A1 | |
| SCHEMBL2977980 | 0.74 | ALDH1A1 (0.76) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL944142 | 0.74 | — | — | |
| Iodide SCHEMBL22345407 | 0.74 | RXFP1 (0.51) | ALDH1A1HPGDHSD17B10RXFP1ALOX15 | |
| SCHEMBL9432049 | 0.72 | HSD17B10 (0.48) | ALDH1A1HPGDHSD17B10RXFP1ALOX15 | |
| SCHEMBL9379792 | 0.72 | MAPT (0.47) | ALDH1A1HPGDHSD17B10RXFP1ALOX15 | |
| SCHEMBL12903095 | 0.71 | KDM4E (0.70) | ALDH1A1HPGDMAPK1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083819-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2083819-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009143178-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143178-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-2083819-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | Omeros Corporation (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008064342-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064342-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2782/4885HPGD 1482/4885HSD17B10 1312/4885 |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | ALDH1A1 2928/4885HPGD 1612/4885HSD17B10 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.